Latest Genta Inc (GNTAQ) Headlines Refractory
Post# of 3
Posted On: 03/10/2014 12:50:53 AM
Latest Genta Inc (GNTAQ) Headlines
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jmtqph/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013" report to their offering. 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL). Scope - A snapshot of the global therapeutic scenario for Refractory Chronic Lymphocytic Leukemia (CLL). - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics. Companies Mentioned Genta Incorporated Celgene Corporation Pharmacyclics, Inc. SBI Biotech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/jmtqph/refractory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Rosen Law Firm, P.A. Announces Class Action Settlement on Behalf of Holders of Common Stock of Genta Incorporated -- GNTAQ
GlobeNewswire - Wed Jul 10, 7:00AM CDT
The Rosen Law Firm, P.A. announces that the Superior Court of New Jersey has approved the following announcement of a proposed class action settlement that would benefit holders of common stock of Genta Incorporated (OTCMKTS:GNTAQ):
2013 Melanoma Global Clinical Trials Review
M2 - Wed Jan 30, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/hsdlwn/melanoma_global) has announced the addition of GlobalData's new report "Melanoma Global Clinical Trials Review, H1, 2013" to their offering. This report provides elemental information and data relating to the clinical trials on Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Melanoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributi
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013
M2 - Wed Sep 04, 9:05AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jmtqph/refractory) has announced the addition of the "Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013" report to their offering. 'Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL). Scope - A snapshot of the global therapeutic scenario for Refractory Chronic Lymphocytic Leukemia (CLL). - A review of the Refractory Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Refractory Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL). - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics. Companies Mentioned Genta Incorporated Celgene Corporation Pharmacyclics, Inc. SBI Biotech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/jmtqph/refractory About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
The Rosen Law Firm, P.A. Announces Class Action Settlement on Behalf of Holders of Common Stock of Genta Incorporated -- GNTAQ
GlobeNewswire - Wed Jul 10, 7:00AM CDT
The Rosen Law Firm, P.A. announces that the Superior Court of New Jersey has approved the following announcement of a proposed class action settlement that would benefit holders of common stock of Genta Incorporated (OTCMKTS:GNTAQ):
2013 Melanoma Global Clinical Trials Review
M2 - Wed Jan 30, 4:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/hsdlwn/melanoma_global) has announced the addition of GlobalData's new report "Melanoma Global Clinical Trials Review, H1, 2013" to their offering. This report provides elemental information and data relating to the clinical trials on Melanoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Melanoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributi
Global Tissue Engineering and Cell Therapy Market 2011-2015 with Advanced Cell Technology Inc. and Medtronic Inc. Dominating
M2 - Wed Jan 16, 6:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/2q5bhp/global_tissue) has announced the addition of the "Global Tissue Engineering and Cell Therapy Market 2011-2015" report to their offering. TechNavio's analysts forecast the Global Tissue Engineering and Cell Therapy market to grow at a CAGR of 18 percent over the period 2011-2015. One of the key factors contributing to this market growth is the significant advancements in RandD. The Global Tissue Engineering and Cell Therapy market has also been witnessing an increase in mergers and acquisitions. However, stringent regulatory requirements could pose a challenge to the growth of this market. The key vendors dominating this market space are Baxter International Inc., DePuy Inc., Medtronic Inc., Stryker Corp., and Zimmer Holdings Inc. The other vendors mentioned in the report are 3DM Inc., Aastrom Biosciences Inc., Acorda Therapeutics Inc., Advanced BioHealing Inc., Advanced Cell Technology Inc., Advanced Medical Solutions Group plc, Aeol
Cystic Fibrosis - Pipeline Review, H2 2012
M2 - Tue Jan 08, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/p9x3z6/cystic_fibrosis) has announced the addition of Global Markets Direct's new report "Cystic Fibrosis - Pipeline Review, H2 2012" to their offering. 'Cystic Fibrosis - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Scope - A snapshot of the global therapeutic scenario for Cystic Fibrosis. - A review of the Cystic Fibrosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monothe
(0)
(0)Genta Incorporated (GNTAQ) Stock Research Links
Scroll down for more posts ▼